AP NEWS

Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting

May 17, 2018

BOTHELL, Wash.--(BUSINESS WIRE)--May 17, 2018--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, from June 1-5, 2018.

“The abstracts being presented at ASCO 2018 highlight the depth of our clinical program in multiple solid tumors and hematological malignancies,” said Robert Lechleider, M.D., Senior Vice President, Clinical Development at Seattle Genetics. “Of note, an oral presentation will feature updated data from a phase 1 study of enfortumab vedotin for patients with metastatic urothelial cancer. Data from this study formed the basis of the recent FDA Breakthrough Therapy Designation for enfortumab vedotin. In addition, multiple posters featuring sub-analyses from the ECHELON-1 trial of ADCETRIS provide continued strong rationale for ADCETRIS combination use in the treatment of patients with frontline Stage 3 and 4 classical Hodgkin lymphoma.”

The abstracts published in advance of the ASCO meeting were made available yesterday on the ASCO website at www.asco.org.

Urothelial Cancer

(Abstract #4504) “Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)”

Presenter: J. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center

Oral Abstract Session: Genitourinary (Nonprostate) Cancer

Date and Time: Sunday, June 3, 9:12 a.m.-9:24 a.m. CDT (session begins at 8:00 a.m.)

Location: Arie Crown Theater

(Abstract #TPS4590) “EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy”

Presenter: J. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center

Poster Session: Genitourinary (Nonprostate) Cancer

Date and Time: Saturday, June 2, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #414a

Hodgkin Lymphoma

(Abstract #7534) “Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma”

Presenter: D. Straus, M.D., Memorial Sloan Kettering Cancer Center

Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #171

(Abstract #7541) “Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results”

Presenter: R. Ramchandren, M.D., Barbara Ann Karmanos Cancer Institute

Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #178

(Abstract #7542) “Long-term follow-up of brentuximab vedotin +/- dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma”

Presenter: J. Friedburg, M.D., University of Rochester Medical Center

Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #179

(Abstract #7539) “Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS)”

Presenter: R. Chen, M.D., Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center

Poster Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #176

Breast Cancer

(Abstract #1015) “Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer”

Presenter: R. Murthy, M.D., University of Texas MD Anderson Cancer Center

Poster Session: Breast Cancer - Metastatic

Date and Time: Saturday, June 2, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #96

Discussed at Poster Discussion at Hall D1 on Saturday, June 2, 1:15 p.m.-2:30 p.m. CDT

Cervical Cancer

(Abstract #TPS5601) “A single-arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax ® -TF-ADC) in previously treated, recurrent or metastatic cervical cancer”

Presenter: R. Coleman, M.D., The University of Texas MD Anderson Cancer Center

Poster Session: Gynecologic Cancer

Date and Time: Monday, June 4, 1:15 p.m.-4:45 p.m. CDT

Location: Hall A, Poster Board #327b

Additional Cancers

(Abstract #3093) “SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors”

Presenter: J. Grilley-Olson, M.D., UNC Lineberger Comprehensive Cancer Center/University of North Carolina Chapel Hill

Poster Session: Developmental Therapeutics - Immunotherapy

Date and Time: Monday, June 4, 8:00 a.m.-11:30 a.m. CDT

Location: Hall A, Poster Board #307

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immunooncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the future development or potential uses of the company investigational drugs including ADCETRIS, enfortumab vedotin, tucatinib, tisotumab vedotin, and the company’s other product candidates and those of its licensees and collaborators as well as other statements that are not historical facts. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, including the risks that Seattle Genetics or its collaborators may experience delays in planned clinical trial initiations or otherwise experience failures or setbacks in preclinical and clinical development programs due to the potential lack of efficacy or risk of adverse events as these product candidates advance in development or other factors. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005298/en/

CONTACT: Seattle Genetics, Inc.

Media:

Monique Greer, 425-527-4641

mgreer@seagen.com

or

Investors:

Peggy Pinkston, 425-527-4160

ppinkston@seagen.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS WASHINGTON

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Seattle Genetics, Inc.

Copyright Business Wire 2018.

PUB: 05/17/2018 08:00 AM/DISC: 05/17/2018 08:01 AM

http://www.businesswire.com/news/home/20180517005298/en

AP RADIO
Update hourly